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Autosomal recessive renal tubular dysgenesis (RTD) is a
severe disorder of renal tubular development characterized
by early onset and persistent fetal anuria leading to
oligohydramnios and the Potter sequence. At birth, blood
pressure is dramatically low and perinatal death occurs in
most cases. Skull ossification defects are frequently
associated with RTD. The disease is genetically
heterogeneous and linked to mutations in the genes
encoding any of the components of the renin–angiotensin
system (RAS). An intense stimulation of renin production is
noted in the kidneys of patients with mutations in the genes
encoding angiotensinogen, angiotensin-converting enzyme,
or AT1 receptor, whereas absence or increased renin
production is associated with REN defects depending on the
type of mutation. The severity of the disease underlines the
importance of a functional RAS in the maintenance of blood
pressure and renal blood flow during fetal life. The absence
or poor development of proximal tubules, as well as renal
vascular changes, may be attributable to renal hypoperfusion
rather than to a morphogenic property of the RAS.
The less severe phenotype in mice devoid of RAS may
be linked to differences between mice and humans in
the time of nephrogenesis and maturation of the RAS.
The identification of the disease on the basis of precise
clinical and histological analyses and the characterization
of the genetic defects allow genetic counseling and early
prenatal diagnosis.
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The renin–angiotensin system (RAS) has a major role in the
control of extracellular volume and salt metabolism, and in
the regulation of blood pressure. Angiotensinogen synthe-
sized by the liver is cleaved in the circulation by renin, an
aspartyl protease produced by juxtaglomerular granular cells
in the afferent arterioles of the kidney. Angiotensinogen
cleavage results in the formation of angiotensin I (ANG I), an
inactive decapeptide further converted by angiotensin-1-
converting enzyme (ACE) into angiotensin II (ANG II), the
active octapeptide. ANG II exerts its effects by binding to two
distinct G-protein-coupled receptors AT1 and AT2. AT1
mediates the classical vasopressive action of ANG II whereas
AT2 has the opposite effect. Renin is the rate-limiting
step in the activation of this catalytic cascade, all other
components being produced in excess in normal conditions.
Its synthesis and release by juxtaglomerular cells are regulated
by signals depending on perfusion pressure in the afferent
arteriole, distal tubule sodium concentration at the level of
the macula densa, and the sympathetic nervous system. In
addition, ANG II exerts a negative feedback control on renin
release. Thus blockade of the RAS by ACE inhibitors or ANG
II type 1 receptor blockers leading to the absence of
production or efficacy of ANG II results in overproduction
of renin.
THE RENIN–ANGIOTENSIN SYSTEM DURING FETAL LIFE
All components of the RAS are expressed early, as soon as 5
weeks of gestation, in human embryos.1,2 Their production is
precisely time-regulated suggesting that ANG II could also
exert its effects as a growth-promoting agent during kidney
development.3 In humans, as in other mammals whose
nephrogenesis is completed before birth, levels of circulating
renin and ANG II are higher during fetal life than during
postnatal life. Conversely, maximum plasma concentrations
of components of the RAS are reached 2–6 weeks after birth
in animals, such as rats or mice, completing nephrogenesis
after birth.4 As discussed below, this difference may partly
explain the species differences in phenotypes associated with
constitutional inactivation of the RAS. Renin does not cross
the placenta, and fetal and maternal RAS are independent as
shown by measurements of the plasma renin concentration
and activity in anephric human and lamb fetuses.5,6
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Several experiments have shown that RAS is functional
during fetal life in mammals. During the second part of
gestation, the RAS of the fetal lamb responds to the same
stimuli (blood volume depletion, furosemide, hypoxemia,
blockade of the RAS, and so on) as the adult.7,8 In the same
way, human fetuses exposed in utero to ACE inhibitors or
AT1 blockers are severely hypotensive at birth and some of
them develop irreversible renal lesions responsible for renal
failure and anuria.9–11 On the other hand, inappropriate
activation of the RAS during fetal life may have deleterious
consequences. In the twin-to-twin transfusion syndrome
resulting from an unbalanced blood supply through placental
anastomoses in monochorionic twins, upregulation of renin
synthesis in the donor twin, a consequence of chronic
hypoperfusion, may negatively affect both fetuses by
aggravating hypoperfusion in the donor and increasing
blood pressure and volemia in the recipient.12
AUTOSOMAL RECESSIVE RENAL TUBULAR DYSGENESIS
In 1983, Allanson et al.13 described the absence or incomplete
differentiation of proximal tubules in two stillborn siblings
who had developed fetal anuria. They suggested that the
tubular lesion could be the marker of a new autosomal
recessive syndrome. Since the initial publication, nearly 100
familial or sporadic cases of the disease have been reported
using various terms, ‘absence of normal-appearing proximal
convoluted tubules’, ‘congenital hypernephronic nephrome-
galy with tubular dysgenesis’, ‘isolated congenital renal
tubular immaturity’, or ‘renal tubular dysgenesis’.14–27 The
last denomination has been retained.
Clinical expression
Clinical expression of the disease is quite stereotyped. Oligohy-
dramnios resulting from reduced urine production is the
revealing symptom. It is detected as early as 20–22 weeks when
the mother is monitored regularly, and persists throughout the
gestation period. Normal amniotic fluid volume before 20
gestational weeks has been documented in affected patients,
precluding early prenatal sonographic diagnosis. Ultrasound
examination shows normal kidneys or mild hyperechogenicity,
poor corticomedullary differentiation, or moderate enlargement.
Gross kidney malformations are consistently absent. Chronic
oligohydramnios leading to fetal compression and decreased
intrauterine mobility results in the Potter sequence (facial
dysmorphia with large low-set ears, redundant skin, limb-
positioning defects, arthrogryposis, and lung hypoplasia). Fetuses
may die in utero. Most neonates die soon after birth with
persistent anuria and respiratory failure. Skull ossification defect
with very large fontanels and sutures at birth is a frequent com-
ponent of the disease. One remarkable feature, in neonates sur-
viving some hours or days on dialysis and respiratory assistance,
is the profound life-threatening and refractory hypotension.
Genetic transmission
At this time 76 sporadic or familial cases of renal tubular
dysgenesis (RTD) have been reported in 48 families and data
concerning 84 additional fetuses/neonates belonging to 56
unrelated families have been reviewed in our laboratory. Male
and female patients are similarly affected. Parental consan-
guinity is present in 32% of families and at least two children
are affected in 40% of consanguineous or nonconsangui-
neous families. Parents are asymptomatic. These data
confirm the autosomal recessive inheritance of the disease,
initially suggested by Allanson et al.13 No phenotypic
difference was observed between apparently sporadic and
familial cases of the disease.
Pathological changes
The affected kidneys are usually of normal size but may be
enlarged. The corticomedullary architecture is preserved. The
morphological hallmark of the disease is the incomplete
development of cortical convoluted proximal tubules that
have been shown by microdissection to be short and
straight.14 By light microscopy, the number of cortical
tubular sections is reduced (Figure 1). Most of them are
lined by poorly differentiated cells in which periodic acid
Schiff staining and lectin or immunohistological labeling fail
to show proximal characteristics: they have no brush border
and they are not stained with winged pea lectin or with
antibodies to proteins (CD10, CD15, or ACE) normally
expressed by proximal tubules16,17,24 (Figure 1c). Conversely,
most tubular sections are labeled with anti-EMA antibodies,
normally a marker of distal tubules and collecting ducts
(Figure 1f). Some distal tubules at their point of contact with
the vascular pole of the glomeruli are enlarged. Lesions are
not restricted to the proximal tubule: Henle loops are rare
and atrophic and collecting ducts, even if normally labeled
with anti-EMA antibodies, are collapsed and surrounded by
increased amounts of interstitial mesenchyme (Figure
1d).14,24 Actually, microdissection studies have shown that
all tubular segments from the glomerulus to the collecting
duct were markedly hypotrophic in the majority of
nephrons.14,19 Curiously, in one of these studies, dissection
of the collecting tree showed an apparent increase in the
number of branches.14 The number of generations of
glomeruli estimated according to the ‘medullary ray glomer-
ular counting method28’ is frequently higher than in age-
matched controls, but may be lower or normal.17,24
Glomeruli are normal, slightly retracted, or enlarged as a
result of mesangial expansion. They appear to be closely
packed because of the reduced number of tubular sections. A
constant feature of the disease, clearly demonstrated by
a-smooth muscle actin labeling, is the marked thickening
and disorganization of the muscular wall of interlobular and
preglomerular arteries, also focally present in arcuate arteries
(Figure 2).
From the phenotype to the genotype
Renal lesions observed in autosomal recessive RTD are not
specific to the genetic disorder. They are very similar to renal
ischemic changes produced in rats by partial occlusion of a
renal artery and described long ago as ‘endocrine kidney’29 or
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to the same changes seen in human kidneys beyond the site
of arterial constriction.30,31 In addition, RTD lesions may be
acquired during fetal life in various circumstances, all
characterized by a primary failure in renal blood supply.
They have been observed in the donor fetus in the twin-to-
twin transfusion syndrome, in major cardiac malformations,
and in hydrops linked to severe hepatic dysfunction in
congenital hemochromatosis.12 RTD also occurs in those
fetuses exposed to ACE inhibitors or to ARBs who develop
severe hypotension, fetal anuria and oligohydramnios, and
skull ossification defect,9,10,11 showing the indispensable role
of the RAS for human survival in the neonatal period. In all
cases of secondary RTD, marked increase in renal renin
production is observed (Figure 3b).
Based on the role of the RAS during kidney development
and the analysis of secondary RTD, it was suggested that
defects in the genes encoding the different components of the
RAS could be the causes of autosomal recessive RTD.18,21,22
To support this hypothesis, we analyzed the renal expression
of renin in RTD patients and observed striking abnormalities
in all of them. They were of two types: complete absence of
the transcript and protein in some cases, or dramatic increase
in renin production with massive staining of juxtaglomerular
cells, and extensive recruitment of arteriolar smooth muscle
cells and mesangial cells in most cases (Figure 3c).24 No
clinical or morphological differences were detected between
patients with excess renin production versus loss of renin.
Globally, these results reinforce our hypothesis and led us to
screen patients for mutations of RAS genes and to show they
were involved in RTD.32
Molecular basis of autosomal recessive RTD
Homozygous or compound heterozygous mutations of the
genes encoding angiotensinogen, renin, ACE, or ANG II
receptor type 1 were observed in most studied RTD
patients.23,25,27,32 All reported mutations were regarded as
pathogenic because they result in the absence of protein, or
affect highly conserved residues, segregated with the disease
in affected families, and are not present in ethnically matched
controls. When parental DNA from familial or apparently
sporadic cases is available, mutations at the heterozygous
state are present in both parents.
Nonsense or splice site loss-of-function REN mutations
were, as expected, characterized by the complete absence
of renin expression in kidney sections. Conversely, REN
missense mutations were associated with strong renal
a b c
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Figure 1 |Renal tubular dysgenesis. Light microscopy. Hematoxylin–eosin (a–b, d–e). Compared to age-matched fetal kidney (a, b),
glomeruli in the renal tubular dysgenesis fetus (d, e) appear closely packed together because of the reduced number of tubular sections.
In the medulla, tubules are dedifferentiated or collapsed (d). At higher magnification, the reduced number of tubular sections is
more evident: some are dedifferentiated (arrows), others, often located near the vascular pole, are hypertrophied (arrowhead) (e).
Immunolabeling (c, f). No tubular labeling with anti-CD10 antibody contrasting with normal glomerular epithelial cell staining (c).
Diffuse tubular labeling with anti-EMA antibody (f). Original magnification: (a, d)  60; (b, e)  270; (c)  300; (f)  180.
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production of the mutant renin. One of these mutations led
to the amino-acid substitution p.D104N in the active
catalytic site of the enzyme. Aspartic acid at this site is
essential for the release of angiotensin. Its substitution
impairs renin function but not production and results in
increased renal synthesis of the inactive mutated renin
because of the loss of the negative feedback inhibition by
ANG II.32 Another missense REN mutation, the p.S135Y,
substitution affected a highly conserved serine.25 It was
associated with intracellular renin retention as shown by the
high renal renin content contrasting with the very low plasma
active renin (o2.5 ng/l; normal range for neonates:
24–850 ng/l). Loss-of-function or missense mutations of the
others genes, ANG, ACE, or AGTR1, were always associated
with massive increase in renin expression.
The same pattern of mutations was observed in familial
and apparently sporadic cases. The clinical phenotype and
the pathological changes were remarkably similar regardless
of renin production or the gene involved, probably because
the final result of all mutations was the absence of ANG II
production or function.
In a few anuric fetuses/neonates with RTD lesions, no RAS
gene mutation was detected. In our experience, the presence
of unusual symptoms, such as anasarca or severe intrauterine
retardation often linked to extensive areas of ischemic
necrosis of the placenta, and/or the absence of changes in
renal renin production, suggests that these atypical cases are
not due to RAS gene mutations. They may be secondary, the
cause of which has been missed. Another possibility is that
other genes are involved, especially in familial cases. AGTR2
encoding the AT2 receptor, or ATP6AP2 encoding the renin/
prorenin receptor, can be excluded because of their location
on the X chromosome and the presumed consequences of
their mutations. The genes encoding the mineralocorticoid
receptor or the endothelin family are possible candidates and
should be investigated after the classical causes of secondary
RTD have been excluded.
Surviving RTD patients with RAS mutations
To date, only four patients have been reported as surviving
after days or weeks on peritoneal dialysis and mechanical
ventilation. Two had AGTmutations, a homozygous missense
(p.R375Q) mutation in one, and compound heterozygous
nonsense mutations in the other. In them, plasma active
renin concentration was very high contrasting with extremely
low or null plasma renin activity (estimated by the amount of
ANG I produced from angiotensinogen by renin in the
patient plasma). Angiotensinogen, ANG I and II levels were
all low.23,25 A gene dose–effect was observed in the brother of
the patient having the p.R375Q mutation in the heterozygous
state: the plasma level of angiotensinogen was reduced but
plasma renin activity was normal due to a compensatory
increased production of renin.25 In the girl patient with the
p.R375Q mutation, dialysis could be ceased on day 4 and
normalization of blood pressure was obtained after 20 days of
vasopressive (adrenaline and dopamine) treatment. At 15
years of age, she is normotensive with moderate chronic renal
failure.25 Two siblings affected with the same disease
developed oligo-anhydramnios were anuric and hypotensive
at birth, and died at respectively 2 and 4 days of age despite
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Figure 2 |Vascular changes in RTD. (a) Massive thickening of
one interlobular artery. (b–d) Immunolabeling with anti-a-smooth
muscle actin antibody (a-SMA). Marked thickening and
disorganization of the muscular wall of interlobular and
preglomerular arteries are underlined by the a-SMA labeling in
renal tubular dysgenesis (RTD) patients (b, c) compared with an
age-paired control (d). Original magnification: (a)  270, (b)
 270, (c)  300, and (d)  270.
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Figure 3 | Immunolabeling with anti-renin antibody. (a) In the
kidney of a control fetus, only a few cells are renin-positive
(arrow). (b) In a fetus with secondary renal tubular dysgenesis
(RTD; exposure to angiotensin-1-converting enzyme (ACE)
inhibitor) there is a strong production of renin: numerous cells are
renin-positive in most juxtaglomerular apparatus with recruitment
of mesangial and smooth-muscle cells. (c) In a fetus with ACE
mutation, the same strong expression of renin is seen not only
in numerous juxtaglomerular cells but also in mesangial cells
and arterial smooth-muscle cells at a distance from glomeruli.
Magnification (a, c)  300; (b)  180.
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supportive treatment. In the second patient with AGT
mutation peritoneal dialysis was required from day 3 up to
day 52 and she has chronic renal failure at 18 months of age.
Interestingly, infusions of fresh frozen plasma were effective
to correct severe neonatal hypotension (but not renal
insufficiency) and had to be maintained up to day 9.23 At
last examination her blood pressure was in the normal range.
One patient had the REN missense p.S135Y mutation in
the homozygous state associated with very low plasma active
renin. She was anuric at birth and recovered diuresis after 5
months on dialysis. Her blood pressure was said to be in the
lower range of normal. She had to be transplanted at 4 years
of age.25 In this family, the following gestation was
terminated at 30-week gestation because of severe recurrence
of the disease.
The last surviving patient had compound heterozygous
ACE deletions (one in-frame and one truncating). She was
anuric at birth, recovered some urination on day 16 but
continued to need peritoneal dialysis at 3 years of age.
Systemic hypotension present at birth persisted for the first 2
weeks and responded poorly to plasma expanders, catecho-
lamines, and glucocorticoids. Diagnosis of RTD was
discussed at 3 years of age on the finding of high plasma
renin activity and high active renin concentration contrasting
with low ACE concentration. It was confirmed by genetic
analysis showing ACE mutations.27
No correlation could be established between the clinical
course of the disease and the type of mutation. Moreover, as
indicated, five affected relatives, with the same AGT or REN
mutations as the surviving patients, died during the perinatal
period.25,27
From the gene defect, back to the phenotype
The presumed consequence of all mutations observed in
RTD is the absence of ANG II production or function, a
defect responsible for the severe refractory hypotension
observed at birth. The progressive normalization of blood
pressure is linked to postnatal development of compensatory
mechanisms.
In addition to its vasopressive action, ANG II regulates
renal growth during development.33–36 Thus, a possible
explanation for the tubular defect is that it results directly
from the loss of the growth-promoting action of ANG II.
However this hypothesis cannot be maintained as the same
tubular anomalies are observed in fetal conditions associated
with stimulation of the RAS (cardiopathies, twin donor in
the twin-to-twin transfusion syndrome, renal artery stenosis,
and so on.), indicating that other factors are involved. Renal
hypoperfusion is probably the common mechanism leading
to RTD lesions whatever their cause: blood depletion (twin-
to-twin transfusion syndrome), renal artery stenosis, or
severe hypotension (autosomal RTD or exposure to RAS
blockers). Low blood pressure may also account for the high
incidence of ischemic or thrombotic complications seen in
RTD patients.20,21,24,26 Skull ossification defect observed in
genetic and secondary RTD is also the consequence of low
blood pressure aggravated by oligohydramnios, because skull
membranous bones require a high oxygen tension for normal
growth.9,10,13,20,22
Renal vascular lesions are present in all cases of genetic or
secondary RDT. They are characterized by marked thickening
of the muscular layer of medium-sized arteries and arterioles,
linked to increased number of smooth muscle layers. They
are similar to renal vascular changes present in hypertensive
nephrosclerosis. Their occurrence in the absence of an
effective RAS is surprising because proliferation and
hypertrophy of vascular smooth muscle cells may be induced
by ANG II through the AT1 receptor. The mechanism may
again implicate hypoperfusion as suggested by the occurrence
of the same vascular lesions in mice with targeted deletions of
the genes encoding components of the RAS.
INACTIVATION OF RAS COMPONENTS IN MICE
The different components of the RAS have been inactivated
in mice.37–47 The resulting phenotype is globally similar
whichever gene is invalidated, but is different from the
phenotype of RTD patients. Embryonic development is
normal in knockout mice but the perinatal mortality rate is
high, around 40% in mice lacking both AT1A and AT1B
receptors43 to 60% in Agt/ mice37 and 80% in Ren1c-null
mice.39 Neonates are not anuric but polyuric and their death
before weaning results from dehydration. Those that survive
spontaneously or by saline infusion show an inability to
concentrate urine and an abnormal sensitivity to salt
depletion. In all cases they are hypotensive. After weeks or
months, according to the gene defect and the genetic
background, they develop progressive renal failure.
At the morphological level, kidneys are normal at birth in
most mouse models, they do not show nephron reduction or
specific changes of proximal tubules. Moderate delay in
postnatal glomerular maturation has been observed in AT1
double nullizygote mice as in Agt-null mice, but the
glomerular maturity index was normal at 3 weeks.38,44 Later
on, they develop renal abnormalities. They consist in
progressive papillary atrophy with tubular atrophy and
interstitial fibrosis associated with pelvic dilatation. Cortical
atrophy occurs secondarily. As previously indicated, marked
thickening of renal arterial walls is present.
Clearly, except for the vascular lesions, the phenotype in
mice is different and less severe than the corresponding one
in humans:48 human neonates are anuric with poor or no
differentiation of proximal tubules whereas mice are polyuric
and develop renal papilla atrophy. Several reasons linked to
differences in the timing of nephrogenesis and RAS
maturation, or in kidney morphology, may explain the more
severe consequences of RAS gene disruption in humans. In
humans, nephrogenesis is complete at 38 gestational weeks
whereas in mice, it continues into the postnatal period for an
additional 2 weeks. Hemodynamic changes linked to
environmental factors occurring after birth may contribute
to normal postnatal proximal tubule maturation. In addition,
in humans, RAS activity reaches its peak during fetal life at
404 Kidney International (2010) 77, 400–406
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the time of active nephrogenesis whereas in mice, it is
achieved 2–6 weeks after birth, suggesting a less mandatory
role in renal development in mice than in humans.4
Conversely, the long and thin inner medulla of mice might
be especially prone to developing ischemic lesions, explaining
renal pathology. Another explanation for renal papilla
atrophy and calyx dilatation in mice has been proposed by
Miyazaki et al,45 based on the similarity with renal lesions in
obstructive nephropathy. Angiotensin type 1 receptors are
present in pelvic smooth muscles and angiotensin induces the
ureteral smooth muscles in organ cultures and the urinary
peristaltic machinery during the perinatal period.49 Lesions
that develop in mice defective for the RAS genes (but not in
anuric RTD patients) should be linked to the defective
development of this peristaltic machinery leading to ‘func-
tional obstruction’ of the urinary tract and its consequences
on kidney structures.
Increase in arterial wall thickness is the common feature
observed in humans and mice without a functional RAS. The
same pattern is present in mineralocorticoid receptor
knockout mice that suffer from major renal hypoperfusion,50
suggesting that vascular changes may result from the
stimulation of growth factors provoked by renal hemody-
namic anomalies rather than from the absence in ANG II.
Actually, enhanced endothelial cell expression of PDGF-B
mRNA has been observed in the thickened arteries and
arterioles of Atg/ mice.38 Mechanisms leading to en-
dothelial cell activation are not all known. Hypoxia may play
a role by activating the family of HIF transcription factors
and by this way, HIF target growth factor genes.51 On the
other hand, hypoperfusion per se may be operative: the
glycocalyx, covering the endothelial surface in close contact
with the flowing blood, has recently been shown to function
as a mechanosensor and a mechanotransducer.52 Syndecans
form the largest group of glycocalyx heparan sulfate
proteoglycans. They sense and transmit the shear stress to
sites where transduction into biochemical signals may
occur.53 Thus they can modulate endothelial cell activity
and growth factor production according to hemodynamic
conditions. Interestingly, kidney vessels are normal in
homozygous mice with ablation of renin-expressing juxta-
glomerular cells54 or inactivation of the Ren-1d gene in 129
mice that possess two renin genes termed Ren-1d and Ren-2.55
This may be explained by the persistent production of renin-
2 (from submandibular gland origin in the first model)
allowing preservation of normal plasma renin concentration
and blood pressure in males and moderate decrease in blood
pressure in females with reduced plasma renin concentration.
DOMINANT RENIN MUTATIONS AND TUBULOINTERSTITIAL
NEPHROPATHY
Parents and siblings of RTD patients with heterozygous
mutation of one or the other RAS gene are asymptomatic.
However, recently dominant REN mutations resulting in
either the deletion or the amino-acid exchange of a single
leucine residue in the signal sequence of renin have been
detected in three unrelated families presenting with early
onset anemia, hyperuricemia, and slowly progressive renal
failure.56 Both mutations are predicted by bioinformatics
analysis to damage targeting and co-translational transloca-
tion of preprorenin into the endoplasmic reticulum, a
prediction confirmed by functional studies. It is suggested
that expression of the mutant proteins has a dominant toxic
effect on renin-expressing cells, reducing their viability,
altering the intrarenal RAS, and gradually leading to renal
failure.
CONCLUSION
Autosomal recessive RDT is a severe disease of renal tubular
development. The diagnosis of this disorder should be
considered for fetuses/neonates who present early oligohy-
dramnios with normal or subnormal kidneys at sonography.
It is easily confirmed by careful pathological analysis and the
exclusion of the possible causes of secondary RDT. The
genetic basis of the disease has been elucidated allowing
precise genetic counseling and early prenatal diagnosis. The
severity of the phenotype linked to RAS mutations shows that
there is no redundancy in the systemic RAS and that the
alternative enzymatic pathways described in vitro are
ineffective in vivo, at least during human fetal life.
Biochemical studies of causative mutations in the different
RAS genes will help to understand the structure–function
relationship of the RAS proteins.
To date, a series of questions may be raised: what is the
actual frequency of RTD? What is the hemodynamic
condition of asymptomatic heterozygote individuals? Are
they protected against hypertension? Are other less severe
mutations in the RAS genes responsible for milder nephro-
pathies: transient neonatal renal failure, unclassified tubulo-
pathies, or tubulointerstitial nephropathies? The finding of
autosomal dominant chronic tubulointerstitial nephropathy
linked to REN mutations affecting the signal sequence of
renin is a first answer to these questions.
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